Cargando…
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Surface-targeting biotherapeutic agents have been successful in treating HER2-amplified cancers through immunostimulation or chemodelivery but have failed to produce effective inhibitors of constitutive HER2-HER3 signaling. We report an extensive structure-function analysis of this tumor driver, rev...
Autores principales: | Campbell, Marcia R., Ruiz-Saenz, Ana, Zhang, Yuntian, Peterson, Elliott, Steri, Veronica, Oeffinger, Julie, Sampang, Maryjo, Jura, Natalia, Moasser, Mark M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865943/ https://www.ncbi.nlm.nih.gov/pubmed/35108526 http://dx.doi.org/10.1016/j.celrep.2021.110285 |
Ejemplares similares
-
Extensive conformational and physical plasticity protects HER2-HER3
tumorigenic signaling
por: Campbell, Marcia R., et al.
Publicado: (2022) -
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022) -
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021) -
Targeting HER proteins in cancer therapy and the role of the non-target HER3
por: Hsieh, A C, et al.
Publicado: (2007) -
Mutant HER2 needs mutant HER3 to be an effective oncogene
por: Trenker, Raphael, et al.
Publicado: (2021)